Drugs / bone marrow mononuclear cells
bone marrow mononuclear cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01719640 | Jan 2011 → Jan 2013 | type 2 diabetes mellitus | Fuzhou General Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow mononuclear cells | “Infusion of autologous bone marrow mononuclear cells (MCs) is an emerging therapeutic approach for DM, which showed promising outcomes with mild side effects.” NCT01719640 ↗ |
| Known as | MCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01719640 ↗ |
| Known as | mononuclear cells | “To investigate the long-term effects of combining bone marrow mesenchymal stem cells (MSCs) with mononuclear cells (MCs) in the treatment of type 2 diabetes mellitus (T2DM).” PMID 39350270 ↗ Sep 2024 |
| Modality | Cell therapy | “The Dual MSC + MC group additionally received MSC and MC infusion” PMID 39350270 ↗ Sep 2024 |